Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

[1]  Jae Cheol Lee,et al.  Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer , 2022, Cancer research and treatment.

[2]  Wanqing Chen,et al.  Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 , 2021, Chinese medical journal.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Jie Li,et al.  Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study , 2021, Cancer management and research.

[5]  Li Zhang,et al.  Therapy of lung cancer in China: introducing the special collection , 2021, Therapeutic advances in medical oncology.

[6]  F. Shepherd,et al.  Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer , 2020, Journal of Clinical Pathology.

[7]  Keunchil Park,et al.  Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis , 2020, Current medical research and opinion.

[8]  Yi-long Wu,et al.  ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. , 2019, Future oncology.

[9]  M. Maemondo,et al.  Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. , 2019, Future oncology.

[10]  P. Jänne,et al.  Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies , 2018, Cancer.

[11]  R. Chiari,et al.  Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience , 2018, Therapeutic advances in respiratory disease.

[12]  Zhongfa Zhang,et al.  Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. , 2018, Lung cancer.

[13]  Young Hak Kim,et al.  Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial , 2018, Cancer science.

[14]  S. Fox,et al.  Australian recommendations for EGFR T790M testing in advanced non–small cell lung cancer , 2017, Asia-Pacific journal of clinical oncology.

[15]  Chia-Chi Lin,et al.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[17]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[18]  F. Ciardiello,et al.  Mechanisms of resistance to EGFR-targeted drugs: lung cancer , 2016, ESMO Open.

[19]  D. Stockeld,et al.  Response to chemoradiatiotherapy in squamous cell carcinoma of the esophagus: evaluation of some prognostic factors , 2009, Clinical and experimental gastroenterology.

[20]  R. Govindan,et al.  Locally advanced non-small cell lung cancer: the past, present, and future. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  E. Takizawa.  [Therapy of lung cancer]. , 1961, Kyobu geka. The Japanese journal of thoracic surgery.